

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTORS;
AND
(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board wishes to announce that with effect from 21 February 2017:

- (1) Mr. Pei Kewei, Mr. Yang Cheng and Mr. Huang Bin have resigned as non-executive Directors; and
- (2) Mr. Jiang Xuejun has been appointed as an independent non-executive Director.

(1) RESIGNATION OF NON-EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Group Limited (the “**Company**”) announces that with effect from 21 February 2017, Mr. Pei Kewei (“**Mr. Pei**”), Mr. Yang Cheng (“**Mr. Yang**”) and Mr. Huang Bin (“**Mr. Huang**”) have resigned as non-executive Directors due to their other personal pursuits and business commitments.

Mr. Pei, Mr. Yang and Mr. Huang have confirmed that they have no disagreement with the Board and there are no matters in relation to their resignation which should be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Pei, Mr. Yang and Mr. Huang for their valuable contribution to the Company during their tenure of office.

(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that with effect from 21 February 2017, Mr. Jiang Xuejun (“**Mr. Jiang**”) has been appointed as an independent non-executive Director.

Mr. Jiang, aged 49, obtained a master’s degree and doctoral degree in Cardiology from Tongji Medical University Affiliated Tongji Hospital in China. He was also a post-doctoral fellow at Pennsylvania State University and New York State University from June 1998 to June 2001. He has been a professor of Cardiology, chief physician and PhD tutor at Wuhan University Renmin Hospital since October 2001. Mr. Jiang mainly focuses on interventional cardiology and his research directions are coronary heart disease intervention and biomaterial application. He undertakes a number of national and provincial studies and has published numerous medical articles.

There is no service contract between Mr. Jiang and the Company. Mr. Jiang has not been appointed for any fixed term but will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The remuneration of Mr. Jiang will be HK\$100,000 per annum which is determined by the Remuneration Committee of the Company on the basis of his duties and responsibilities within the Company and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, (i) Mr. Jiang does not hold any other position in the Company or its subsidiaries; (ii) Mr. Jiang does not hold any other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) Mr. Jiang does not, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance; (iv) Mr. Jiang does not have any relationship with any directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) or controlling shareholders (as defined in the Listing Rules) of the Company; and (v) Mr. Jiang has not possessed any other professional qualifications.

Mr. Jiang has confirmed that he has met the independence criteria as set out in Rule 3.13 of the Listing Rules and there are no matters that are required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that needed to be brought to the attention of the Shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Jiang to join the Board.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended from 9:00 a.m. on 4 July 2016 pending the publication of the annual results of the Company for the year ended 31 March 2016.

By order of the Board
China Health Group Limited
Weng Yu
Executive Director

Hong Kong, 21 February 2017

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Weng Yu, Mr. Wang Yongqing, Mr. Chung Ho, Mr. Wang Jingming and Mr. Zhang Fan; eight non-executive directors, namely, Mr. Ying Wei, Mr. Zhang Song, Ms. Wei Changying, Mr. Xing Yong, Mr. Wang Zili, Mr. Wang Xiaolin, Mr. Wang Yuexiang and Mr. Li Xuguang; and seven independent non-executive directors, namely, Mr. Xiao Zuhe, Mr. Wang Qingyou, Mr. Zou Lian, Ms. Yang Huimin, Mr. Liang Qi, Mr. Xin Hua and Mr. Jiang Xuejun.